小分子GLP-1受体激动剂:一个有前途的药理学方法
Oana Cristina Șeremet1, Ciprian Pușcașu1, Corina Andrei1
1Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, 6 Traian Vuia Street, 020945 Bucharest, Romania.
Medicina (Kaunas, Lithuania)
|November 27, 2025
概括
小分子葡萄糖类-1受体 (GLP-1R) 激动剂提供口服治疗2型糖尿病和肥胖症. 这些新型化合物显示出对代谢障碍治疗的前景,有可能改善患者的坚持和成本效益.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
背景情况:
- 葡萄糖类-1受体 (GLP-1R) 激动剂已成为2型糖尿病和肥胖症的注射疗法.
- 最近药物化学的进步导致了小分子GLP-1R激动剂的开发.
- 这些小分子比激动剂具有潜在的优势,包括口服和改善患者坚持治疗.
研究的目的:
- 审查小分子GLP-1R激动剂的药理学概况.
- 总结关于这些药物的当前临床和临床前研究进展.
- 突出其作为代谢障碍治疗替代疗法的潜力.
主要方法:
- 这是一个叙事评论.
- 关于小分子GLP-1R激动剂的文献搜索.
- 对药理动力学数据和临床/临床前研究结果的分析.
主要成果:
- 小分子GLP-1R激动剂在增强胰岛素分泌和促进体重减轻方面表现出与激动剂相当的疗效.
- 优点包括口服生物可用性,可能导致更好的患者坚持和成本效益.
- 目前正在进行的临床和临床前研究表明具有显著的治疗潜力.
结论:
- 小分子GLP-1R激动剂代表了对治疗2型糖尿病和肥胖症的有前途的新类药物.
- 它们的口服管理模式可以彻底改变代谢障碍的治疗.
- 需要进一步的研究来充分确定它们的长期有效性和安全性.
相关概念视频
Glucagon-like Receptor Agonists
824
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
824
Oral Hypoglycemic Agents: Glinides
573
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
573
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
509
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
509
Dipeptidyl Peptidase 4 Inhibitors
566
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
566
Oral Hypoglycemic Agents: Biguanides and Glitazones
567
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
567
G Protein-coupled Receptors
16.4K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
16.4K


